Skip to main content

Ionis Pharmaceuticals Value Stock - Dividend - Research Selection

Ionis pharmaceuticals

ISIN: US4622221004 , WKN: A2ACMZ

Market price date:
Market price:  

Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Key figures
Cash flow
Balance sheet
Income statement
Div. Yield%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization USD
Raw Data Source
Stock Split

Description of the company

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein. It is also developing inotersen, an antisense drug Ionis to treat patients with hereditary transthyretin amyloidosis; and volanesorsen, an antisense drug for the treatment of familial chylomicronemia syndrome and familial partial lipodystrophy. In addition, the company is developing drugs for various indications, such as cardiometabolic diseases caused by lipid disorders; cardiovascular disease, clotting disorders, and Alzheimer\'s and Parkinson\'s diseases; and acromegaly, amyotrophic lateral sclerosis, beta-thalassemia, and Huntington\'s disease. Ionis Pharmaceuticals, Inc. has a collaboration agreement with AstraZeneca to discover and develop antisense therapies for treating cardiovascular and metabolic diseases, and cancer; and Biogen Inc. to develop and commercialize therapies for neurological disorders, SMA, and neurodegenerative diseases. The company was formerly known as Isis Pharmaceuticals, Inc. and changed its name to Ionis Pharmaceuticals, Inc. in December 2015. Ionis Pharmaceuticals, Inc. was founded in 1989 and is headquartered in Carlsbad, California.
The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,


Wall Street Analysts Are Neutral on Top Healthcare Picks

Looking for stock market analysis and research with proves results? offers in-depth financial research with over 30years of proven results.

Ionis announces FDA acceptance of New Drug Application for eplontersen for the treatment of hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN)

Ionis Pharmaceuticals (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for eplontersen, an investigational antisense medicine for the treatment of people living with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN). The application has been given a Prescription Drug User Fee Act (PDUFA) action date of Dec. 22, 2023.

Ionis: FDA to Review Eplontersen in ATTRv-PN >IONS

By Colin Kellaher Ionis Pharmaceuticals Inc. on Tuesday said the U.S. Food and Drug Administration will review its application seeking approval of its...

Ionis Pharmaceuticals: FDA accepts NDA for eplontersen

Looking for stock market analysis and research with proves results? offers in-depth financial research with over 30years of proven results.

RXDX vs. IONS: Which Biotech Stock is Better?

Looking for stock market analysis and research with proves results? offers in-depth financial research with over 30years of proven results.

Merck: All Eyes On Key Clinical Catalyst In March

Merck is an American biopharma powerhouse that has generated consistent compounding growth. Click here to read my analysis of MRK stock.

Ionis to present at upcoming investor conferences

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will present at the following investor conferences:

Royalty Pharma: Strong Q4 Results, Reiterating A Buy Rating

Royalty Pharma recently reported positive FY 2022 earnings. We like its focus on Lpa class. Read to know why we maintain a buy rating on RPRX stock.

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q4 2022 Earnings Call Transcript

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q4 2022 Earnings Call Transcript February 22, 2023 Operator: Good morning, and welcome to Ionis Pharmaceuticals Fourth Quarter and Full Year 2022 Financial Results Conference Call. . As a reminder, this call is being recorded. At this time, I would like to turn the call over to Wade Walke, Senior Vice […]

Ionis (IONS) Q4 Earnings Top Estimates, Sales Lag, Stock Down

Ionis (IONS) Q4 loss is narrower than expected. However, sales miss estimates. Revenue guidance for 2023 looks soft. Stock down.